🚀 VC round data is live in beta, check it out!
BrainsWay Valuation Multiples
Discover revenue and EBITDA valuation multiples for BrainsWay and similar public comparables like SI-BONE, Japan Lifeline, Lumibird, Cytek Biosciences and more.
BrainsWay Overview
About BrainsWay
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Founded
2006
HQ
Employees
120
Website
Financials (LTM)
EV
$558M
BrainsWay Financials
BrainsWay reported last 12-month revenue of $56M and EBITDA of $9M.
In the same LTM period, BrainsWay generated $43M in gross profit, $9M in EBITDA, and $9M in net income.
Revenue (LTM)
BrainsWay P&L
In the most recent fiscal year, BrainsWay reported revenue of $52M and EBITDA of $11M.
BrainsWay expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $56M | XXX | $52M | XXX | XXX | XXX |
| Gross Profit | $43M | XXX | $39M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $9M | XXX | $11M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $9M | XXX | $8M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BrainsWay Stock Performance
BrainsWay has current market cap of $620M, and enterprise value of $558M.
Market Cap Evolution
BrainsWay's stock price is $15.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $558M | $620M | 0.0% | XXX | XXX | XXX | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBrainsWay Valuation Multiples
BrainsWay trades at 9.9x EV/Revenue multiple, and 62.1x EV/EBITDA.
EV / Revenue (LTM)
BrainsWay Financial Valuation Multiples
As of April 20, 2026, BrainsWay has market cap of $620M and EV of $558M.
Equity research analysts estimate BrainsWay's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BrainsWay has a P/E ratio of 68.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $620M | XXX | $620M | XXX | XXX | XXX |
| EV (current) | $558M | XXX | $558M | XXX | XXX | XXX |
| EV/Revenue | 9.9x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | 62.1x | XXX | 48.7x | XXX | XXX | XXX |
| EV/EBIT | 92.8x | XXX | 129.0x | XXX | XXX | XXX |
| EV/Gross Profit | 13.1x | XXX | 14.2x | XXX | XXX | XXX |
| P/E | 68.7x | XXX | 81.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 34.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BrainsWay Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BrainsWay Margins & Growth Rates
BrainsWay's revenue in the last 12 month grew by 26%.
BrainsWay's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
BrainsWay's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BrainsWay's rule of X is 88% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BrainsWay Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 77% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 88% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 67% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BrainsWay Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BrainsWay | XXX | XXX | XXX | XXX | XXX | XXX |
| SI-BONE | XXX | XXX | XXX | XXX | XXX | XXX |
| Japan Lifeline | XXX | XXX | XXX | XXX | XXX | XXX |
| Lumibird | XXX | XXX | XXX | XXX | XXX | XXX |
| Cytek Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Advanced Medical Solutions Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BrainsWay M&A Activity
BrainsWay acquired XXX companies to date.
Last acquisition by BrainsWay was on XXXXXXXX, XXXXX. BrainsWay acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BrainsWay
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBrainsWay Investment Activity
BrainsWay invested in XXX companies to date.
BrainsWay made its latest investment on XXXXXXXX, XXXXX. BrainsWay invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BrainsWay
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BrainsWay
| When was BrainsWay founded? | BrainsWay was founded in 2006. |
| Where is BrainsWay headquartered? | BrainsWay is headquartered in Israel. |
| How many employees does BrainsWay have? | As of today, BrainsWay has over 120 employees. |
| Who is the CEO of BrainsWay? | BrainsWay's CEO is Hadar Levy. |
| Is BrainsWay publicly listed? | Yes, BrainsWay is a public company listed on Nasdaq. |
| What is the stock symbol of BrainsWay? | BrainsWay trades under BWAY ticker. |
| When did BrainsWay go public? | BrainsWay went public in 2019. |
| Who are competitors of BrainsWay? | BrainsWay main competitors are SI-BONE, Japan Lifeline, Lumibird, Cytek Biosciences. |
| What is the current market cap of BrainsWay? | BrainsWay's current market cap is $620M. |
| What is the current revenue of BrainsWay? | BrainsWay's last 12 months revenue is $56M. |
| What is the current revenue growth of BrainsWay? | BrainsWay revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of BrainsWay? | Current revenue multiple of BrainsWay is 9.9x. |
| Is BrainsWay profitable? | Yes, BrainsWay is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BrainsWay? | BrainsWay's last 12 months EBITDA is $9M. |
| What is BrainsWay's EBITDA margin? | BrainsWay's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of BrainsWay? | Current EBITDA multiple of BrainsWay is 62.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.